Skip to main content
Toggle navigation
Login
Home
Tweets by 2022 Canadian Cardiovascular Congress
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
In Person Event
Livestream
On Demand
Ticketed Event
HF
HF
Type here to filter the list
(P093) A PROPENSITY-MATCHED COHORT STUDY TO ASSESS THE EFFECTIVENESS OF A COMMUNITY HOSPITAL BASED HEART FUNCTION CLINIC
Favorite
(P094) ADHERENCE TO GUIDELINE-DIRECTED MEDICAL THERAPY AMONG PATIENTS FOLLOWED AT AN AMBULATORY HEART FUNCTION CLINIC
Favorite
(P095) AN ASSESSMENT OF GOAL-DIRECTED BEHAVIOURS THAT PROMOTE HEALTH-RELATED QUALITY OF LIFE: A PROOF-OF-CONCEPT STUDY
Favorite
(P096) ASSOCIATION OF DURATION AND INTENSITY OF EXERCISE WITH SEVERITY OF PHENOTYPIC EXPRESSION IN HYPERTROPHIC CARDIOMYOPATHY
Favorite
(P097) BALLISTOCARDIOGRAPHY TO CHARACTERIZE PULMONARY ARTERY PRESSURE IN ADVANCED HEART FAILURE PATIENTS AND HEALTHY ADULTS
Favorite
(P099) CARDIAC RESYNCHRONISATION AND LEFT VENTRICULAR EJECTION FRACTION IMPROVEMENT WITH SINGLE VENTRICULAR PHYSIOLOGICAL PACING LEAD
Favorite
(P100) DEVELOPMENT OF A DIAGNOSTIC SCREENING ALGORITHM FOR THE IDENTIFICATION OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY IN HIGH-RISK PATIENT POPULATIONS
Favorite
(P101) EARLY DETECTION OF POLYNEUROPATHY IN PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY
Favorite
(P102) ECHOCARDIOGRAPHIC EVALUATION OF LEFT VENTRICULAR REMODELING AFTER VALSARTAN/SACUBITRIL INITIATION IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
Favorite
(P103) EFFECTIVENESS, SAFETY, AND TOLERABILITY OF SACUBITRIL/VALSARTAN OVER 3 YEARS OF FOLLOW-UP IN CANADIAN PRACTICE: INSIGHTS FROM THE PARTHENON REGISTRY
Favorite
(P104) HIGH-INTENSITY INTERVAL TRAINING FOR HEART FAILURE AND POST-HEART TRANSPLANT: A SYSTEMATIC REVIEW AND META-ANALYSIS
Favorite
(P105) IMPROVED SURVIVAL WITH ~5 YEARS OF CONTINUOUS TAFAMIDIS TREATMENT AMONG PATIENTS WITH NYHA CLASS III TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Favorite
(P106) IS FLAXSEED EQUIVALENT AND/OR SYNERGISTIC WITH ACE INHIBITION IN THE TREATMENT OF CHEMOTHERAPY MEDIATED CARDIOTOXICITY?
Favorite
(P107) MEDICAL MANAGEMENT OF HEART FAILURE WITH CONCURRENT DIABETES MELLITUS IN CANADIAN PRIMARY CARE
Favorite
(P108) MYOCARDIAL RECOVERY AND SURVIVAL AFTER WEANING OF LEFT VENTRICULAR ASSIST DEVICE THERAPY IN PATIENTS WITH TOXIC AND NON-TOXIC CARDIOMYOPATHIES, A CANADIAN EXPERIENCE
Favorite
(P109) PHARMACIST-LED TITRATION CLINIC FOR HFREF MEDICATION : RESULTS FROM ITS FIRST 2 YEARS OF EXISTENCE
Favorite
(P110) PREDICTING 1-YEAR MORTALITY IN AMBULATORY HEART FAILURE PATIENTS: EMPIRIC MODELS OUTPERFORM PHYSICIAN INTUITIVE ESTIMATES
Favorite
(P111) PREDICTING LONG-TERM SURVIVAL AFTER DE NOVO CARDIOVERTER DEFIBRILLATOR IMPLANTATION FOR PRIMARY PREVENTION
Favorite
(P112) PREVALENCE OF ANEMIA IN CARDIAC AMYLOIDOSIS AND ASSOCIATION WITH CLINICAL FACTORS AND OUTCOMES
Favorite
(P113) PROGRESSION OF TRICUSPID REGURGITATION AND CLINICAL OUTCOMES IN PATIENTS WITH LONGSTANDING PERSISTENT ATRIAL FIBRILLATION
Favorite
(P114) PUMPING IRON: A QUALITY IMPROVEMENT STUDY FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN AMBULATORY HEART FAILURE PATIENTS
Favorite
(P115) SEVERITY OF LEFT VENTRICULAR DYSFUNCTION IN PATIENTS WITH TACHYCARDIA-INDUCED CARDIOMYOPATHY: IMPACTS ON REMODELING AFTER ATRIAL FLUTTER ABLATION
Favorite
(P116) SEX DIFFERENCES IN PULMONARY AND SYSTEMIC VASCULAR FUNCTION AT REST AND DURING EXERCISE IN HEALTHY OLDER ADULTS
Favorite
(P117) SINGLE CENTRE COMPARISON OF PATIENTS MANAGED BY A CODE SHOCK TEAM VERSUS STANDARD OF CARE
Favorite
(P118) SODIUM RESTRICTION IN PATIENTS WITH HEART FAILURE:A SYSTEMATIC REVIEW AND META-ANALYSIS OFRANDOMIZED CLINICAL TRIALS
Favorite
(P119) SODIUM-GLUCOSE TRANSPORT PROTEIN 2 INHIBITOR ELIGIBILITY FOR PATIENTS HOSPITALIZED WITH ACUTE HEART FAILURE
Favorite
(P120) TIME TO GUIDELINE-DETERMINED MEDICAL THERAPY IN PATIENTS WITH DE NOVO HEART FAILURE: A RETROSPECTIVE POPULATION-BASED STUDY FROM ALBERTA, CANADA
Favorite
(P121) UTILITY OF A MEDICAL OPTIMIZATION CLINIC IN HEART FAILURE PATIENTS WITH AN IMPLANTED CARDIAC DEVICE
Favorite
(P122) WHY IS HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) MORE COMMON IN WOMEN THAN MEN? EXPLORING ABNORMALITIES IN PULSITILE ARTERIAL LOAD AS DISTINCT FEATURE OF THE HFPEF SYNDROME IN WOMEN
Favorite